Dr McMenamin joined the School of Public Health in 2020 as a Postdoctoral Fellow. Prior to this she studied at The University of Manchester (UK) where she was awarded a BSc in Actuarial Science and Mathematics in 2014 and completed a two year NIHR Research Methods Fellowship, from which she gained an MSc Statistics. She obtained her PhD in Biostatistics from University of Cambridge (UK) in 2019 where she subsequently held a Research Associate position until moving to Hong Kong.
Dr McMenamin’s current research focus involves improving methods for estimating vaccine effectiveness and quantifying intra-season vaccine effectiveness waning. Her previous work has focused on causal inference in relation to mental health trials, latent variable modelling for mixed outcome types and online software development for novel method implementation.
- McMenamin M, Barrett JK, Berglind A, Wason JMS. Employing a latent variable framework to improve efficiency in composite endpoint analysis. Stat Methods Med Res. 2020 https://doi.org/10.1177/0962280220970986. Epub ahead of print. PMID: 33234028.
- Wason J, McMenamin M, Dodd S. Analysis of responder-based endpoints: improving power through utilising continuous components. Trials. 2020; 21:427 https://doi.org/10.1186/s13063-020-04353-8
- McMenamin M, Grayling MJ, Berglind A, Wason JMS. Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial. medRxiv [Preprint] 2020 https://doi.org/10.1101/2020.07.28.20163378
- McMenamin M, Barrett JK, Berglind A, Wason JMS. Sample Size Estimation using a Latent Variable Model for Mixed Outcome Co-Primary, Multiple Primary and Composite Endpoints. ArXiv [Preprint] 2019 https://arxiv.org/abs/1912.05258
- McMenamin M Berglind A, Wason JMS. Improving the analysis of composite endpoints in rare disease trials. Orphanet Journal of Rare Diseases. 2018;13(81) https://doi.org/10.1186/s13023-018-0819-1
- Spencer HM, McMenamin M, Emsley R, et al. Cognitive Behavioral Therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?. Schizophr Res. 2018;202:385-386. https://doi.org/10.1016/j.schres.2018.07.016